Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy*

Jason N. Barreto, Kristen B. McCullough, Candy S. Peskey, Ross A. Dierkhising, Kristin C. Mara, Michelle A. Elliott, Dennis A. Gastineau, Aref Al-Kali, Naseema Gangat, Louis Letendre, William Hogan, Mark R Litzow, Mrinal M Patnaik

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The optimal antithrombin(AT) activity parameters for replacement as thromboprophylaxis following asparaginase remains unclear. This single-center, retrospective study evaluated two sets of AT replacement thresholds and targets in adults receiving asparaginase-containing chemotherapy. AT supplementation adhered to institutional standards, which lowered the AT activity target from 100% to 80% in 6/2014. Ninety-two patients were evaluated. Cumulative thrombosis incidence was 16% at 6 months (95%CI:6.8–24.0, maximum follow-up 315 days) with similar incidence between the 80% and 100% target groups, 14% (2 of the 14) and 13% (10 of the 78), respectively, with a small non-Line-Related DVT incidence (3%). Most thrombotic events occurred during induction chemotherapy and demonstrated no associations with replacement target, cumulative days or cumulative area under AT activity target, number of asparaginase doses, or cumulative asparaginase dose. Median estimated AT replacement expenditure was $34,963USD (IQR $16,260USD to $79,319USD) per patient. Cost-effectiveness and optimization of AT replacement for thromboprophylaxis following asparaginase requires prospective evaluation.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalLeukemia and Lymphoma
DOIs
StateAccepted/In press - Apr 13 2017

Fingerprint

Asparaginase
Antithrombins
Hematologic Neoplasms
Safety
Therapeutics
Incidence
Induction Chemotherapy
Health Expenditures
Cost-Benefit Analysis
Thrombosis
Retrospective Studies
Drug Therapy

Keywords

  • Antithrombin
  • asparaginase
  • hematological malignancy
  • thromboprophylaxis
  • thrombosis

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy* . / Barreto, Jason N.; McCullough, Kristen B.; Peskey, Candy S.; Dierkhising, Ross A.; Mara, Kristin C.; Elliott, Michelle A.; Gastineau, Dennis A.; Al-Kali, Aref; Gangat, Naseema; Letendre, Louis; Hogan, William; Litzow, Mark R; Patnaik, Mrinal M.

In: Leukemia and Lymphoma, 13.04.2017, p. 1-10.

Research output: Contribution to journalArticle

Barreto, Jason N. ; McCullough, Kristen B. ; Peskey, Candy S. ; Dierkhising, Ross A. ; Mara, Kristin C. ; Elliott, Michelle A. ; Gastineau, Dennis A. ; Al-Kali, Aref ; Gangat, Naseema ; Letendre, Louis ; Hogan, William ; Litzow, Mark R ; Patnaik, Mrinal M. / Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy* In: Leukemia and Lymphoma. 2017 ; pp. 1-10.
@article{a8333197c7094d16a8a60ac01c0ce51f,
title = "Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy*",
abstract = "The optimal antithrombin(AT) activity parameters for replacement as thromboprophylaxis following asparaginase remains unclear. This single-center, retrospective study evaluated two sets of AT replacement thresholds and targets in adults receiving asparaginase-containing chemotherapy. AT supplementation adhered to institutional standards, which lowered the AT activity target from 100{\%} to 80{\%} in 6/2014. Ninety-two patients were evaluated. Cumulative thrombosis incidence was 16{\%} at 6 months (95{\%}CI:6.8–24.0, maximum follow-up 315 days) with similar incidence between the 80{\%} and 100{\%} target groups, 14{\%} (2 of the 14) and 13{\%} (10 of the 78), respectively, with a small non-Line-Related DVT incidence (3{\%}). Most thrombotic events occurred during induction chemotherapy and demonstrated no associations with replacement target, cumulative days or cumulative area under AT activity target, number of asparaginase doses, or cumulative asparaginase dose. Median estimated AT replacement expenditure was $34,963USD (IQR $16,260USD to $79,319USD) per patient. Cost-effectiveness and optimization of AT replacement for thromboprophylaxis following asparaginase requires prospective evaluation.",
keywords = "Antithrombin, asparaginase, hematological malignancy, thromboprophylaxis, thrombosis",
author = "Barreto, {Jason N.} and McCullough, {Kristen B.} and Peskey, {Candy S.} and Dierkhising, {Ross A.} and Mara, {Kristin C.} and Elliott, {Michelle A.} and Gastineau, {Dennis A.} and Aref Al-Kali and Naseema Gangat and Louis Letendre and William Hogan and Litzow, {Mark R} and Patnaik, {Mrinal M}",
year = "2017",
month = "4",
day = "13",
doi = "10.1080/10428194.2017.1312384",
language = "English (US)",
pages = "1--10",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy*

AU - Barreto, Jason N.

AU - McCullough, Kristen B.

AU - Peskey, Candy S.

AU - Dierkhising, Ross A.

AU - Mara, Kristin C.

AU - Elliott, Michelle A.

AU - Gastineau, Dennis A.

AU - Al-Kali, Aref

AU - Gangat, Naseema

AU - Letendre, Louis

AU - Hogan, William

AU - Litzow, Mark R

AU - Patnaik, Mrinal M

PY - 2017/4/13

Y1 - 2017/4/13

N2 - The optimal antithrombin(AT) activity parameters for replacement as thromboprophylaxis following asparaginase remains unclear. This single-center, retrospective study evaluated two sets of AT replacement thresholds and targets in adults receiving asparaginase-containing chemotherapy. AT supplementation adhered to institutional standards, which lowered the AT activity target from 100% to 80% in 6/2014. Ninety-two patients were evaluated. Cumulative thrombosis incidence was 16% at 6 months (95%CI:6.8–24.0, maximum follow-up 315 days) with similar incidence between the 80% and 100% target groups, 14% (2 of the 14) and 13% (10 of the 78), respectively, with a small non-Line-Related DVT incidence (3%). Most thrombotic events occurred during induction chemotherapy and demonstrated no associations with replacement target, cumulative days or cumulative area under AT activity target, number of asparaginase doses, or cumulative asparaginase dose. Median estimated AT replacement expenditure was $34,963USD (IQR $16,260USD to $79,319USD) per patient. Cost-effectiveness and optimization of AT replacement for thromboprophylaxis following asparaginase requires prospective evaluation.

AB - The optimal antithrombin(AT) activity parameters for replacement as thromboprophylaxis following asparaginase remains unclear. This single-center, retrospective study evaluated two sets of AT replacement thresholds and targets in adults receiving asparaginase-containing chemotherapy. AT supplementation adhered to institutional standards, which lowered the AT activity target from 100% to 80% in 6/2014. Ninety-two patients were evaluated. Cumulative thrombosis incidence was 16% at 6 months (95%CI:6.8–24.0, maximum follow-up 315 days) with similar incidence between the 80% and 100% target groups, 14% (2 of the 14) and 13% (10 of the 78), respectively, with a small non-Line-Related DVT incidence (3%). Most thrombotic events occurred during induction chemotherapy and demonstrated no associations with replacement target, cumulative days or cumulative area under AT activity target, number of asparaginase doses, or cumulative asparaginase dose. Median estimated AT replacement expenditure was $34,963USD (IQR $16,260USD to $79,319USD) per patient. Cost-effectiveness and optimization of AT replacement for thromboprophylaxis following asparaginase requires prospective evaluation.

KW - Antithrombin

KW - asparaginase

KW - hematological malignancy

KW - thromboprophylaxis

KW - thrombosis

UR - http://www.scopus.com/inward/record.url?scp=85019154192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019154192&partnerID=8YFLogxK

U2 - 10.1080/10428194.2017.1312384

DO - 10.1080/10428194.2017.1312384

M3 - Article

C2 - 28482728

AN - SCOPUS:85019154192

SP - 1

EP - 10

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -